Showing 1311-1320 of 1861 results for "".
- Vaseline Takes on Lack of Diversity in Skin Color Images with New Databasehttps://practicaldermatology.com/news/vaseline-takes-on-lack-of-diversity-in-skin-color-images-with-new-database/2461160/Vaseline is launching See My Skin, a database designed to search for conditions on skin of color and connect patients with dermatologists. Vaseline is introducing See My Skin with HUED, a digital health company focused on improving quality of care for Black, Latinx and Indigen
- Lilly's Lebrikizumab Combined with Topical Corticosteroids Produces Significant Improvements in AD Disease Severityhttps://practicaldermatology.com/news/lillys-lebrikizumab-combined-with-topical-corticosteroids-produces-significant-improvements-in-ad-disease-severity/2461154/Atopic dermatitis patients taking lebrikizumab plus topical steroids showed significant improvements in disease severity, according to study results from the ADhere trial presented at the 4th Annual Revolutionizing Atopic Dermatitis (RAD) Conference. At 16 weeks, 70 percent of
- Blueberry Extract May Improve Wound Healinghttps://practicaldermatology.com/news/blueberry-extract-may-improve-wound-healing/2461152/Treating wounds with an extract taken from wild blueberries may improve healing, according to a new study presented at the American Physiological Society’s annual meeting at Experimental Biology 2022. Researchers from the University of Maine previously found that a phenolic extrac
- Aveeno Opens Applications for 2022 Skin Health Startup Accelerator Pitch Competitionhttps://practicaldermatology.com/news/aveeno-opens-applications-for-2022-skin-health-startup-accelerator-pitch-competition/2461150/The Aveeno brand has announced its second year of the Aveeno Skin Health Start
- Dermatological Society of New Jersey Kicks Off Virtual Conference Saturdayhttps://practicaldermatology.com/news/dermatological-society-of-new-jersey-kicks-off-virtual-conference-saturday/2461147/The DSNJ annual educational conference is a hybrid event this year, with in person as well as online conference experiences open to attendees across the US. The conference is Saturday, April 9. Penn Medicine Princeton Health, accredited by the Medical Society of New Jersey, designa
- Practical Dermatology® Names New Interim Digital Practice Editorhttps://practicaldermatology.com/news/practical-dermatology-names-new-interim-digital-practice-editor/2461145/Practical Dermatology® magazine is proud to announce that Vishal Anil Patel, MD will serve as interim editor of our Digital Practice column. Dr. Patel is director of cutaneous oncology at GW Cancer Center, director of dermatologic surgery at GW department of der
- Boehringer Ingelheim’s Effisayil Offers Sustained Relief from GPP Flareshttps://practicaldermatology.com/news/boehringer-ingelheims-effisayil-offers-sustained-releif-from-gpp-flares/2461143/Effisayil (Spesolimab) clears skin pustules in patients with generalized pustular psoriasis (GPP) flares within the first week after treatment, and these benefits are sustained over 12 weeks, according to data presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting in Bost
- Aquavit Submits NDA for New Neurotoxinhttps://practicaldermatology.com/news/aquavit-submits-nda-for-new-neurotoxin/2461141/Aquavit Pharmaceuticals, Inc. has submitted its IND for a new botulinum toxin (DTX-021) to the FDA for approval. The company also unveiled its development programs at the Annual meeting of the American Academy of Dermatology in Boston. DTX-021, a botulinum toxin type A drug intende
- Dermavant's Tapinarof Shows Durable Improvement in PsO in Long-term Extension Studyhttps://practicaldermatology.com/news/dermavants-tapinarof-shows-durable-improvement-in-pso-in-long-term-extension-study/2461140/Results from the Phase 3 PSOARING 3 long-term extension study demonstrate durable improvements across efficacy outcomes, quality of life measures, and tolerability scores with investigational tapinarof cream 1% once daily (QD) for the treatment of plaque psoriasis in adults. The data, f
- Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/long-term-complete-skin-clearance-data-for-bimekizumab-in-moderate-to-severe-plaque-psoriasis/2461137/UCB presented 11 abstracts on bimekizumab in the treatment of adults with moderate to severe plaque psoriasis at the 2022 American Academy of Dermatology (AAD) Annual Meeting in Boston, MA, including a late breaking oral platform presentation and 10 posters. The platform presentation details new